Sutro Biopharma Return On Asset vs. Price To Book

STRO Stock  USD 2.51  0.02  0.79%   
Based on the key profitability measurements obtained from Sutro Biopharma's financial statements, Sutro Biopharma may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Sutro Biopharma's ability to earn profits and add value for shareholders.
For Sutro Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sutro Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sutro Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sutro Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sutro Biopharma over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Sutro Biopharma Price To Book vs. Return On Asset Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Sutro Biopharma's current stock value. Our valuation model uses many indicators to compare Sutro Biopharma value to that of its competitors to determine the firm's financial worth.
Sutro Biopharma is rated fourth in return on asset category among its peers. It is rated below average in price to book category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sutro Biopharma's earnings, one of the primary drivers of an investment's value.

Sutro Price To Book vs. Return On Asset

Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Sutro Biopharma

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.18
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Sutro Biopharma

P/B

 = 

MV Per Share

BV Per Share

 = 
1.98 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Sutro Price To Book Comparison

Sutro Biopharma is currently under evaluation in price to book category among its peers.

Sutro Biopharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Sutro Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sutro Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Sutro Biopharma's change in net profit over the period of time. It can combine multiple indicators of Sutro Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. Sutro Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people.

Sutro Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Sutro Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sutro Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sutro Biopharma's important profitability drivers and their relationship over time.

Use Sutro Biopharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.

Sutro Biopharma Pair Trading

Sutro Biopharma Pair Trading Analysis

The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.
The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Sutro Biopharma position

In addition to having Sutro Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Oil And Gas Thematic Idea Now

Oil And Gas
Oil And Gas Theme
Companies involved in drilling, production, and distribution of oil and gas pipelines. The Oil And Gas theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Oil And Gas Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Sutro Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sutro Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sutro Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sutro Biopharma Stock:
Check out World Market Map.
To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
To fully project Sutro Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sutro Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sutro Biopharma's income statement, its balance sheet, and the statement of cash flows.
Potential Sutro Biopharma investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Sutro Biopharma investors may work on each financial statement separately, they are all related. The changes in Sutro Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sutro Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.